Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Josina C. Reddy"'
Autor:
Daniel D. Von Hoff, Jennifer A. Low, Kenn L. Zerivitz, Richard A. Graham, Walter C. Darbonne, Ilsung Chang, Julie R. Brahmer, Christine L. Hann, Mitesh J. Borad, Glen J. Weiss, Raoul Tibes, Josina C. Reddy, Charles M. Rudin, Patricia M. LoRusso
Related CCR Translation from Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b60e90d4e50d5b1c5344236ef2c6534
https://doi.org/10.1158/1078-0432.22442930.v1
https://doi.org/10.1158/1078-0432.22442930.v1
Autor:
Patricia M. LoRusso, Jennifer A. Low, Josina C. Reddy, Charles M. Rudin, Daniel D. Von Hoff, Karin Jorga, Jin Yan Jin, Sravanthi Cheeti, Bert L. Lum, Richard A. Graham
Related CCR Translation from Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445d125ac34f7cf31441c6e5b21da204
https://doi.org/10.1158/1078-0432.22442520.v1
https://doi.org/10.1158/1078-0432.22442520.v1
Autor:
Patricia M. LoRusso, Jennifer A. Low, Josina C. Reddy, Charles M. Rudin, Daniel D. Von Hoff, Karin Jorga, Jin Yan Jin, Sravanthi Cheeti, Bert L. Lum, Richard A. Graham
Purpose: In a phase I trial for patients with refractory solid tumors, hedgehog pathway inhibitor vismodegib (GDC-0449) showed little decline in plasma concentrations over 7 days after a single oral dose and nonlinearity with respect to dose and time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::180a91f52a60c76662c36a5c9d52002f
https://doi.org/10.1158/1078-0432.c.6519234
https://doi.org/10.1158/1078-0432.c.6519234
Autor:
Josina C. Reddy, Ilsung Chang, Robert L. Yauch, Ling Fu, Paul Sabbatini, Brian Slomovitz, Beth Karlan, Amnon Amit, Robert Holloway, Louis Fehrenbacher, Stanley B. Kaye
PDF file - 44K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d2ea37b522d8ab7f12669c10ebfb3cb
https://doi.org/10.1158/1078-0432.22456128
https://doi.org/10.1158/1078-0432.22456128
Autor:
Josina C. Reddy, Ilsung Chang, Robert L. Yauch, Ling Fu, Paul Sabbatini, Brian Slomovitz, Beth Karlan, Amnon Amit, Robert Holloway, Louis Fehrenbacher, Stanley B. Kaye
Purpose: Hedgehog pathway inhibition has been suggested as a potential maintenance treatment approach in ovarian cancer through disruption of tumor–stromal interactions. Vismodegib is an orally available Hedgehog pathway inhibitor with clinical act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06c61be58c1015a1886ed4fd4e38c19c
https://doi.org/10.1158/1078-0432.c.6523209
https://doi.org/10.1158/1078-0432.c.6523209
Autor:
Daniel D. Von Hoff, Jennifer A. Low, Kenn L. Zerivitz, Richard A. Graham, Walter C. Darbonne, Ilsung Chang, Julie R. Brahmer, Christine L. Hann, Mitesh J. Borad, Glen J. Weiss, Raoul Tibes, Josina C. Reddy, Charles M. Rudin, Patricia M. LoRusso
Purpose: The hedgehog (Hh) signaling pathway, a key regulator of cell growth and differentiation during development is implicated in pathogenesis of certain cancers. Vismodegib (GDC-0449) is a small-molecule inhibitor of smoothened, a key component o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4191bddf50f3d8031f85f0205fe342b4
https://doi.org/10.1158/1078-0432.c.6519551
https://doi.org/10.1158/1078-0432.c.6519551
Autor:
Ruoding Tan, Cindy Yun, Arpamas Seetasith, Daniel Sheinson, Robert Walls, Innocent Ngwa, Josina C Reddy, Qing Zhang, Matthew H Secrest, Peter Lambert, Khaled Sarsour
Publikováno v:
The Oncologist. 27:236-243
Background Amid continued uncertainty about the management of cancer patients during the pandemic, this study sought to obtain real-world data on the use of immune checkpoint inhibitors (ICIs) before COVID-19 diagnosis and its association with severi
Autor:
Luna Musib, Josina C. Reddy, Sravanthi Cheeti, Sandhya Girish, Jin Y. Jin, Pascal Chanu, Rene Bruno, Tong Lu, Ivor Caro, Xin Wang
Publikováno v:
Journal of Investigative Dermatology. 141:930-933
Summary Long-term use of vismodegib is associated with treatment-emergent adverse drug reactions in clinical trials of patients with locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC). Treatment interruptions have been recommende
Autor:
Christine L. Hann, Kenn L. Zerivitz, Glen J. Weiss, Ilsung Chang, Josina C. Reddy, Walter C. Darbonne, Mitesh J. Borad, Charles M. Rudin, Patricia LoRusso, Julie R. Brahmer, Jennifer A. Low, Raoul Tibes, Richard A. Graham, Daniel D. Von Hoff
Publikováno v:
Clinical Cancer Research. 17:2502-2511
Purpose: The hedgehog (Hh) signaling pathway, a key regulator of cell growth and differentiation during development is implicated in pathogenesis of certain cancers. Vismodegib (GDC-0449) is a small-molecule inhibitor of smoothened, a key component o
Autor:
Daniel D. Von Hoff, Frederic J. de Sauvage, Josina C. Reddy, Walter C. Darbonne, Howard Mackey, Charles M. Rudin, Jennifer A. Low, Bertram L. Lum, Christine L. Hann, James C. Marsters, Patricia LoRusso, Mitesh J. Borad, Julie R. Brahmer, Robert L. Yauch, Glen J. Weiss, Raoul Tibes
Publikováno v:
New England Journal of Medicine. 361:1164-1172
Background Mutations in hedgehog pathway genes, primarily genes encoding patched homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma. In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449,